Heart rhythm disturbances as manifestations of cardiotoxicity of chemotherapy in the treatment of an ovarian cancer patient
Authors:
Company:
1 Scientific Institution Research Institute for Complex Issues of Cardiovascular Diseases, Sosnovyy bul’var, 6, Kemerovo, 650002, Russian Federation
2 Regional Clinical Oncology Dispensary, Volgogradskaya ulitsa, 35, Kemerovo, 650036, Russian Federation
For correspondence: Sign in or register.
Type: Case reports
DOI:
For citation: Polikutina O.M., Evtushenko V.V., Zobnina A.V., Borzyanitsa S.M., Slepynina Yu.S., Barbarash O.L. Heart rhythm disturbances as manifestations of cardiotoxicity of chemotherapy in the treatment of a patient with ovarian cancer. Creative Cardiology. 2018; 12 (2): 177–82 (in Russ.). DOI: 10.24022/1997-3187-2018-12-2-177-182
Received / Accepted: May 07, 2018 / May 14, 2018
Keywords: chemotherapy-induced cardiotoxicity cardiooncology heart rhythm disturbance
Abstract
A clinical case of cardiotoxicity of chemotherapy in the treatment of a patient with ovarian cancer is presented. Outpatient management problems are discussed, and differential diagnostics questions are considered.
Acknowledgements. The study had no sponsorship.
Conflict of interest. The authors declare no conflict of interest.
References
2016 ESC position paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC committee for practice guide- lines. Russian Journal of Cardiology. 2017; 3: 105–39. DOI: 10.15829/1560-4071-2017-3-105-139 (in Russ.)
Witteles R.M., Bosch X. Myocardial protection during cardiotoxic chemotherapy. Circulation. 2015; 132: 1835–45. DOI: 10.1161/CIRCULA-TIONAHA.114.010486
Moslehi J., Lenihan D.J. Cardio-oncology: time to get more mechanistic. JACC: Basic to trans- lational science. 2017; 2 (1): 54–5. DOI: 10.1016/j.jacbts.2017.01.002
Seliverstova D.V., Evsina O.V. Cardiotoxicity of chemotherapy. Russian Heart Journal. 2016; 15 (1): 50–7.DOI: 10.18087/rhj.2016.1.2115 (in Russ.)
Feyskhanova L.I., Malov A.A., Kharisova E.Kh. Heart injury induced by chemotherapy in oncology diseases. Russian Heart Failure Journal. 2015; 16 (5): 296–302. DOI: 10.18087/rhfj.2015.5.2109 (in Russ.).
Nikitovic D., Juranek I., Wilks M.F., Tzardi M., Tsatsakis A., Tzanakakis G.N. Anthracycline- dependent cardiotoxicity and extracellular matrix remodeling. Chest. 2014; 146 (4): 1123–30. DOI: 10.1378/chest.14-0460
Stenina M.B., Gladkov O.A., Kopp M.V., Koroleva I.V., Malygin S.E., Portnoy C.M. et al. Practical recommendations for correction of cardiovascular toxicity induced by chemotherapy and targeted drugs. Moscow; 2014: 360–8 (in Russ.).
Fradley M.G., Neilan T.G. Cardiovascular out- comes in anthracycline-related cardiomyopathy. JACC: Clinical Electrophysiology. 2017; 3 (2): 151–3. DOI: 10.1016/j.jacep.2016.10.004
About Authors
Ol’ga M. Polikutina, Dr. Med. Sci., Head of Laboratory,
Veronika V. Evtushenko, Researcher,
Anna V. Zobnina, Physician of Functional Diagnostics,
Stanislav M. Borzyanitsa, Oncologist,
Yulia S. Slepynina, Cand. Med. Sc., Senior Researcher,
Ol’ga L. Barbarash, Dr. Med. Sci., Professor, Corresponding Member of Russian Academy of Sciences, Director,
